CAN
CRSP icon

Cetera Advisor Networks’s CRISPR Therapeutics CRSP Stock Holding History

Cetera Advisor Networks’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.51M Sell
22,209
-135
-0.6% -$9.66K 0.01% 1170
2023
Q4 		$1.4M Buy
22,344
+12,971
+138% +$717K 0.01% 1162
2023
Q3 		$425K Buy
9,373
+2,274
+32% +$117K ﹤0.01% 1889
2023
Q2 		$399K Sell
7,099
-35
-0.5% -$1.99K ﹤0.01% 1886
2023
Q1 		$323K Sell
7,134
-404
-5% -$19.6K ﹤0.01% 2008
2022
Q4 		$306K Buy
7,538
+306
+4% +$16.2K ﹤0.01% 1977
2022
Q3 		$473K Sell
7,232
-700
-9% -$50.7K 0.01% 1319
2022
Q2 		$482K Sell
7,932
-550
-6% -$32.3K 0.01% 1298
2022
Q1 		$532K Buy
8,482
+2,367
+39% +$149K 0.01% 1257
2021
Q4 		$463K Sell
6,115
-4,618
-43% -$403K 0.01% 1325
2021
Q3 		$1.2M Buy
10,733
+6,789
+172% +$853K 0.02% 761
2021
Q2 		$638K Buy
3,944
+938
+31% +$114K 0.01% 1048
2021
Q1 		$366K Sell
3,006
-2,311
-43% -$349K 0.01% 1025
2020
Q4 		$814K Sell
5,317
-1,166
-18% -$138K 0.02% 606
2020
Q3 		$542K Sell
6,483
-20
-0.3% -$1.77K 0.01% 684
2020
Q2 		$478K Buy
6,503
+1,751
+37% +$102K 0.01% 712
2020
Q1 		$202K Sell
4,752
-821
-15% -$42.4K 0.01% 984
2019
Q4 		$341K Buy
+5,573
New +$304K 0.01% 895
2019
Q3 		– Sell
-4,743
Closed -$222K – 1204
2019
Q2 		$222K Buy
+4,743
New +$190K 0.01% 1040
2018
Q4 		– Sell
-11,873
Closed -$523K – 1046
2018
Q3 		$523K Buy
11,873
+2,793
+31% +$146K 0.02% 615
2018
Q2 		$536K Buy
+9,080
New +$517K 0.03% 455

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cetera Advisor Networks's CRSP Position: Q1 2024 in Review

Cetera Advisor Networks reduced its CRISPR Therapeutics (CRSP) stake by 0.6% in Q1 2024, selling an estimated $9.66K and leaving 22,209 shares worth $1.51M. The position accounts for 0.01% of the portfolio, ranked #1170.

Cetera Advisor Networks first reported a position in CRSP in Q2 2018 and has held it in 21 quarters since. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Cetera Advisor Networks held 22,209 shares of CRISPR Therapeutics worth $1.51M as of Q1 2024.
  • Cetera Advisor Networks sold 135 CRISPR Therapeutics shares in Q1 2024, an estimated $9.66K.
  • CRISPR Therapeutics made up 0.01% of Cetera Advisor Networks's portfolio in Q1 2024, its #1170 holding.
  • Cetera Advisor Networks first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.